SpectraCure (Sweden) Performance
| SPEC Stock | SEK 1.45 0.01 0.69% |
The entity has a beta of 0.0075, which indicates not very significant fluctuations relative to the market. As returns on the market increase, SpectraCure's returns are expected to increase less than the market. However, during the bear market, the loss of holding SpectraCure is expected to be smaller as well. At this point, SpectraCure AB has a negative expected return of -0.7%. Please make sure to validate SpectraCure's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if SpectraCure AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SpectraCure AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 157.2 M | |
| Total Cashflows From Investing Activities | -8.5 M |
SpectraCure |
SpectraCure Relative Risk vs. Return Landscape
If you would invest 243.00 in SpectraCure AB on August 31, 2024 and sell it today you would lose (99.00) from holding SpectraCure AB or give up 40.74% of portfolio value over 90 days. SpectraCure AB is generating negative expected returns and assumes 4.8341% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than SpectraCure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SpectraCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SpectraCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SpectraCure AB, and traders can use it to determine the average amount a SpectraCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1458
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPEC |
Estimated Market Risk
| 4.83 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SpectraCure is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SpectraCure by adding SpectraCure to a well-diversified portfolio.
SpectraCure Fundamentals Growth
SpectraCure Stock prices reflect investors' perceptions of the future prospects and financial health of SpectraCure, and SpectraCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpectraCure Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0851 | |||
| Operating Margin | (15.50) % | |||
| Current Valuation | 561.51 M | |||
| Shares Outstanding | 97.13 M | |||
| Price To Book | 4.21 X | |||
| Price To Sales | 396.86 X | |||
| Revenue | 5.75 M | |||
| EBITDA | (20.43 M) | |||
| Cash And Equivalents | 129.69 M | |||
| Total Debt | 2.49 M | |||
| Book Value Per Share | 1.61 X | |||
| Cash Flow From Operations | (18.6 M) | |||
| Earnings Per Share | (0.26) X | |||
| Total Asset | 190.52 M | |||
| Retained Earnings | (14 M) | |||
| Current Asset | 5 M | |||
| Current Liabilities | 3 M | |||
About SpectraCure Performance
Assessing SpectraCure's fundamental ratios provides investors with valuable insights into SpectraCure's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the SpectraCure is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about SpectraCure AB performance evaluation
Checking the ongoing alerts about SpectraCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpectraCure AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpectraCure AB generated a negative expected return over the last 90 days | |
| SpectraCure AB may become a speculative penny stock | |
| SpectraCure AB has high historical volatility and very poor performance | |
| The company reported the revenue of 5.75 M. Net Loss for the year was (23.34 M) with profit before overhead, payroll, taxes, and interest of 2.99 M. | |
| SpectraCure AB has accumulated about 129.69 M in cash with (18.6 M) of positive cash flow from operations. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing SpectraCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpectraCure's stock is overvalued or undervalued compared to its peers.
- Examining SpectraCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpectraCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpectraCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpectraCure's stock. These opinions can provide insight into SpectraCure's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.